Director
Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, MD, United States
Ann Marie Stanley is a Director of Translational Medicine within AstraZeneca’s Vaccines & Immune Therapies unit. She holds dual undergraduate degrees in Chemistry and Physics from the University of Virginia as well as a Ph.D. in Biophysics from Johns Hopkins University. Dr Stanley is a highly collaborative translational scientist with over 15 years of experience spanning clinical development, regulatory strategy, and scientific policy.
In her current role at AstraZeneca, Ann Marie leads the development of translational and biomarker strategies to support clinical assay development, transfer, and validation for global clinical programs within the Vaccines & Immune Therapies unit. She has co-authored more than 20 scientific publications, with recent work focusing on exploratory serologic biomarkers and monoclonal antibody epitope conservation across AstraZeneca’s COVID-19, RSV, and antibacterial research programs.
Her contributions to the nirsevimab clinical development program include supporting the analysis of treatment-emergent RSV variants and leading the development and validation of a method to deplete YTE-modified monoclonal antibodies from clinical samples. In this poster presentation she will present her recent work evaluating anti-RSV prefusion protein binding and neutralizing antibody responses in nirsevimab-immunized infants following nirsevimab depletion.
Disclosure information not submitted.
Monday, October 20, 2025
3:15 PM - 3:27 PM US ET